## AMENDMENT TO THE CLAIMS

*A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.*

**Claim 1 (currently amended):** A method of identifying a compound which modulates binding of a ~~natural~~ ligand selected from the group consisting of EGF, heparin-binding EGF, TGFα, vaccinia virus growth factor, betacellulin and amphiregulin to the EGF receptor, ~~ErbB3 or ErbB4~~[[,]] or which modulates signal transduction ~~via~~ by binding to the EGF receptor, ~~ErbB2, ErbB3 or ErbB4~~[[,]] which method comprises the steps of:

(A) assessing the stereochemical complementarity between the compound and ~~the~~ a molecule, wherein the molecule comprises:

(i) amino acids 1-621 of the EGF receptor positioned at atomic coordinates ~~substantially~~ as shown in Figure 6; or

(ii) one or more subsets of said amino acids related to the coordinates shown in Figure 6 by whole body translations and/or rotations;

~~(iii) amino acids present in the amino acid sequence of ErbB2, ErbB3 or ErbB4, which form an equivalent three dimensional structure to that of the receptor site defined by amino acids 1-621 of the EGF receptor positioned at atomic coordinates substantially as shown in Figure 6;~~

(B) ~~obtaining~~ selecting a compound assessed in step (A) which possesses stereochemical complementarity to the molecule; ~~and~~

(C) testing the compound *in vivo* or *in vitro* for its ability to

(i) modulate binding of a ~~natural~~ ligand selected from the group consisting of EGF, heparin-binding EGF, TGFα, vaccinia virus growth factor, betacellulin and amphiregulin to the EGF receptor, ~~ErbB3 or ErbB4~~[[,]]or

(ii) modulate signal transduction ~~via~~ by binding to the EGF receptor[[,]] ~~ErbB2,ErbB3 or ErbB4~~[[,]]; and

(D) selecting and obtaining a compound tested in step (C) that has the ability to

(i) modulate binding of a ligand selected from the group consisting of EGF, heparin-binding EGF, TGFα, vaccinia virus growth factor, betacellulin and amphiregulin to the EGF receptor, or

(ii) modulate signal transduction by binding to the EGF receptor.

**Claims 2 - 53 (canceled).**

**Claim 54 (previously added):** The method according to claim 1, wherein the testing in (C) is carried out *in vitro*.

**Claim 55 (previously added):** The method according to claim 54, wherein the testing is performed by a high throughput assay.

**Claim 56 (previously added):** The method according to claim 1, wherein the testing in (C) is carried out *in vivo*.

**Claim 57 (previously added):** The method of claim 1, in which step (C)(ii) involves testing the compound for the ability to modulate EGF receptor mediated cell proliferation.

**Claim 58 (currently amended):** The method of claim 1, wherein the one or more subsets of amino acids in step (A)(ii) is defined by amino acids 313-621 of the EGF receptor positioned at atomic coordinates ~~substantially~~ as shown in Figure 6.

**Claim 59 (canceled).**

**Claim 60 (currently amended):** The method of claim 1, wherein the one or more subsets of amino acids in step (A)(ii) is defined by amino acids 1-475 of the EGF receptor positioned at atomic coordinates ~~substantially~~ as shown in Figure 6.

**Claim 61 (canceled).**

**Claim 62 (canceled).**

**Claim 63 (previously added):** The method of claim 1, wherein the one or more subsets of amino acids in step (A)(ii) are the amino acids that form the β-sheet of the L1 domain of the EGF receptor.

**Claim 64 (canceled).**

**Claim 65 (previously added):** The method of claim 1, wherein the one or more subsets of amino acids in step (A)(ii) are the amino acids that form the β-sheet of the L2 domain of the EGF receptor.

**Claim 66 (canceled).**

**Claim 67 ( currently amended):** The method of claim 1, which further includes the step of modifying the compound selected in step (B) or step (D) such that ~~to enhance~~ binding to a lower face containing the second β-sheet of the L1 and/or L2 domains is enhanced in the modified compound compared to the unmodified compound, wherein the structure of the face is characterized by a plurality of solvent-exposed hydrophobic residues.

**Claim 68 (previously added):** The method of claim 67, in which the hydrophobic residues include:

(i) Tyr64, Leu66, Tyr89, Tyr93; and/or

(ii) Leu348, Phe380 and Phe412.

**Claim 69 (previoiusly added):** The method of claim 1 in which the compound is identified from test compounds in a database.

**Claim 70 (currently amended):** The method of claim 1, which further includes the step of selecting a compound that increases signal transduction via by binding to the EGF receptor[[,]] ~~ErbB2, ErbB3 or ErbB4~~.

**Claim 71 (currently amended):** The method of claim 1, which further includes the step of selecting a compound that decreases signal transduction ~~via~~ by binding to the EGF receptor[[,]] ~~ErbB2, ErbB3 or ErbB4~~.

**Claim 72 (currently amended):** The method of claim 1, which further includes the step of selecting a compound that inhibits or prevents the binding of a ligand selected from the group consisting of EGF, heparin-binding EGF, TGFα, vaccinia virus growth factor, betacellulin and amphiregulin ~~natural ligand~~ to the EGF receptor[[,]] ~~ErbB3 or ErbB4~~.

**Claim 73 (currently amended):** A method of identifying a compound which binds to ~~a molecule of the EGF receptor family selected form the group consisting of~~ the EGF receptor, ~~ErbB2, ErbB3 and ErbB4~~[[,]] which method comprises the steps of:

(A) assessing the stereochemical complementarity between the compound and the molecule, wherein the molecule comprises:

(i) amino acids 1-621 of the EGF receptor positioned at atomic coordinates ~~substantially~~ as shown in Figure 6; or

(ii) one or more subsets of said amino acids related to the coordinates shown in Figure 6 by whole body translations and/or rotations; ~~or~~

~~(iii) amino acids present in the amino acid sequence of ErbB2, ErbB3 or ErbB4, which form an equivalent three dimensional structure to that of the receptor site defined by amino acids 1-621 of the EGF receptor positioned at atomic coordinates substantially as shown in Figure 6;~~

(B) ~~obtaining one ore more compounds which possesses stereochemical complementarity to the molecule~~ selecting a compound assessed in step (A) which possesses stereochemical complementarity to the molecule; and

(C) selecting a compound from step B that has [[a]] an experimentally determined $K_d$ or $K_I$ of less than $10^{-6}$ M for ~~a molecule of the EGF receptor family selected from the group consisting of~~ the EGF receptor[[,]] ~~ErbB2, ErbB3 and ErbB4~~.

**Claim 74 (previously added):** A method as claimed in claim 73, wherein $K_d$ is less than $10^{-8}$M.

**Claim 75 (previously added):** The method of claim 73, wherein $K_I$ is less than $10^{-8}$M.